Sarhan Neven, Essam Abou Warda Ahmed, Alsahali Saud, Alanazi Abdalla Salah
Clinical Pharmacy Department, Faculty of Pharmacy, Misr International University, Cairo 11828, Egypt.
Clinical Pharmacy Department, Faculty of Pharmacy, October 6 University, Giza 12585, Egypt.
Pharmaceuticals (Basel). 2023 Feb 9;16(2):262. doi: 10.3390/ph16020262.
Vitamin D has recently been found to influence the renin-angiotensin system (RAS); it can reduce the effects of renin-angiotensin system inhibitors (RASI) by decreasing plasma renin. This study examines the effect of vitamin D supplements on cardiac fibrosis markers, echocardiographic parameters, and epigenetic markers in patients with established acute coronary syndrome (ACS). It also looks at the incidence of vitamin D receptor (VDR) gene polymorphisms and and its association with the development of secondary major acute cardiovascular events (MACE) and heart failure (HF). A randomized controlled trial in which patients were divided into two groups was performed. Group 1 comprised of 125 ACS patients who received ACS standard therapy alone, while Group 2 consisted of 125 ACS patients who received ACS standard therapy plus vitamin D according to their vitamin D levels. Patients were monitored for 24 months to find subsequent MACE and HF. Vitamin D therapy for ACS patients resulted in a substantial decline in end systolic and end diastolic volumes ( = 0.0075 and 0.002, respectively), procollagen type III N-terminal peptide (PIIINP) and soluble ST2 levels ( = 0.007 and 0.001, respectively), as well as in ejection fraction and vitamin D level ( = 0.0001 and 0.008, respectively). In addition, vitamin D treatment was linked to a significant decline in the levels of noncoding RNA, such as mir361, lncRNA MEG3, and lncRNA Chaer ( = 2.9 × 10, 2.2 × 10, and 1.2 × 10, respectively). Furthermore, patients who suffered MACE had significantly higher levels of the and genotypes ( = 4.8 × 10 and 0.003, respectively), while patients with HF had significantly higher levels of the genotype ( = 4.2 × 10). Supplementing ACS patients with vitamin D has been demonstrated to limit cardiac fibrosis and echocardiographic parameters, as well as epigenetic markers. Additionally, MACE and HF among ACS patients may be related to genetic variations among VDR gene polymorphisms.
最近发现维生素D会影响肾素-血管紧张素系统(RAS);它可通过降低血浆肾素水平来减弱肾素-血管紧张素系统抑制剂(RASI)的作用。本研究探讨了维生素D补充剂对已确诊急性冠状动脉综合征(ACS)患者的心脏纤维化标志物、超声心动图参数和表观遗传标志物的影响。研究还观察了维生素D受体(VDR)基因多态性的发生率及其与继发性主要急性心血管事件(MACE)和心力衰竭(HF)发生发展的关联。进行了一项随机对照试验,将患者分为两组。第1组由125例仅接受ACS标准治疗的ACS患者组成,而第2组由125例根据其维生素D水平接受ACS标准治疗加维生素D的ACS患者组成。对患者进行24个月的监测以发现随后发生的MACE和HF。对ACS患者进行维生素D治疗后,收缩末期和舒张末期容积大幅下降(分别为 = 0.0075和0.002),III型前胶原N端肽(PIIINP)和可溶性ST2水平下降(分别为 = 0.007和0.001),同时射血分数和维生素D水平也下降(分别为 = 0.0001和0.008)。此外,维生素D治疗与非编码RNA水平的显著下降有关,如mir361、lncRNA MEG3和lncRNA Chaer(分别为 = 2.9×10、2.2×l0和1.2×10)。此外,发生MACE的患者的 和 基因型水平显著更高(分别为 = 4.8×10和0.003),而HF患者的 基因型水平显著更高( = 4.2×10)。已证明给ACS患者补充维生素D可限制心脏纤维化、超声心动图参数以及表观遗传标志物。此外,ACS患者中的MACE和HF可能与VDR基因多态性的基因变异有关。